ABUS vs GRMN · P/E 5.4, rev $6.2M vs P/E 28, rev $6.30B
Arbutus Biopharma Corp (ABUS) versus Garmin Ltd (GRMN) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
Garmin Ltd (GRMN) is a scientific & technical instruments company listed on US.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported GRMN revenue for 2024-12-28 was $6.30B. Net income was $1.41B. Revenue was up 20.4% from 2023-12-30 to 2024-12-28. GRMN currently screens at market cap $41.35B and trailing P/E 28.3.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. GRMN currently screens at market cap $41.35B and trailing P/E 28.3.
Not investment advice. Open the ABUS and GRMN stock pages for the full models.
Not investment advice.